High-Value Federal Grants ($5M+) — August 21, 2026

CACI secured a $674M cost-plus-fixed-fee delivery order from GSA for IT and telecom services, providing predictable, lower-risk revenue through May 2024. The full-and-open competition win signals technical merit, though $477.8M in subawards may dilute margins.

BARDA awarded a $263.6M initial obligation (up to $1.04B total) to Sabin Vaccine Institute for Marburg virus R&D, indicating sustained government commitment to pandemic preparedness. While the nonprofit recipient limits direct equity exposure, subcontractors in biotech may benefit.

Teledyne's $371.5M NASA ISS support contract (2013-2022) has only $151.3M outlayed, less than half the obligated value, and has already ended. No follow-on awards are identified, creating a revenue gap for the company.

HSGS-AMERESCO's $149.2M firm-fixed-price VA energy savings contract carries high pricing risk, as cost overruns are borne by the contractor. The 19-month performance period and SDVOSB set-aside limit scalability.

Highrise Consulting has outlayed 65% ($89.6M) of its $138.6M NIH IT delivery order, indicating high utilization and low cancellation risk. The labor-hours pricing provides stable margins through September 2027.

CACI's $674M GSA contract shows a negative net outlay of -$414,919, which is unusual and may indicate accounting adjustments or early-stage activity. This could signal delayed revenue recognition or contract issues.

Teledyne Brown Engineering's NASA contract has only $151.3M outlayed against $371.5M obligated, suggesting under-execution or delayed funding. The contract has already ended with no follow-on identified, creating a revenue gap.

HSGS-AMERESCO's $149.2M firm-fixed-price VA contract exposes the contractor to cost overruns, especially in construction and energy retrofits. The 19-month timeline is aggressive for hospital renovations.

Two of five contracts (40% of total value) are from HHS agencies (BARDA and NIH), indicating a concentration in civilian health IT and biodefense. A shift in HHS budget priorities could impact these programs.

CACI's $674M GSA IT contract positions it for follow-on work in federal digital modernization, especially as the contract runs through May 2024. Recompete or extensions could provide additional revenue visibility.

The Sabin Vaccine Institute's $1.04B BARDA contract for Marburg virus R&D may generate subcontracts for publicly traded biotech firms, offering indirect investment exposure to biodefense growth.

HSGS-AMERESCO's SDVOSB set-aside win at the VA highlights policy-driven opportunities for veteran-owned small businesses in energy efficiency. Similar VA ESPC contracts could follow, but scalability is limited.

Two contracts totaling $813M (CACI's $674M GSA IT and Highrise's $138.6M NIH IT) demonstrate sustained civilian demand for IT and cloud services, with cost-plus or labor-hours pricing reducing earnings risk.

BARDA's $263.6M initial obligation (up to $1.04B total) to Sabin Vaccine Institute for Marburg virus R&D signals increased government commitment to biodefense, though the nonprofit recipient limits direct equity exposure.

Teledyne Brown Engineering's $371.5M ISS support contract ended in 2022 with only $151.3M outlayed, highlighting the risk of under-execution and the lack of clear follow-on opportunities as ISS operations wind down.

{"entity" => "CACI International Inc.", "reason" => "CACI's $674M GSA IT contract has a negative net outlay and runs through May 2024; recompete or extension decisions are critical.", "trigger" => "Contract recompete announcement or extension before May 2024"}

{"entity" => "Teledyne Technologies", "reason" => "Teledyne Brown Engineering's NASA ISS contract has ended with no follow-on identified, creating a revenue gap.", "trigger" => "New NASA contract awards or ISS budget announcements"}

{"entity" => "Albert B. Sabin Vaccine Institute", "reason" => "The $1.04B BARDA contract's option exercises will determine long-term funding for Marburg virus R&D.", "trigger" => "Option exercise announcements or BARDA budget updates"}

{"entity" => "HSGS-AMERESCO, LLC", "reason" => "The $149.2M VA fixed-price contract carries high execution risk; cost overruns or delays could impact profitability.", "trigger" => "VA project milestone reports or change order filings"}

{"entity" => "HIGHRISE CONSULTING INC", "reason" => "The $138.6M NIH IT contract has strong utilization (65% outlayed) but faces renewal risk in September 2027.", "trigger" => "NIH IT budget allocations or contract extension announcements"}